Happy to share our latest findings of the group, ‘The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse.’ published in the Journal of Experimental & Clinical Cancer Research. In our latest manuscript, we unveil DNMT3B as a novel epigenetic regulator of MYC deregulation in MM and a therapeutic vulnerability in patients with high DNMT3B and MYC levels.
Key Highlights:
We provide evidence that DNMT3B is upregulated in relapsed multiple myeloma (MM) patients, correlating with aggressive disease and poor outcome.
We show that DNMT3B supports MM cell growth and survival, by sustaining cell cycle progression and stemness-related transcriptional programs and stabilizing MYC protein.
DNMT3B targeting displays strong anti-MM activity, sensitizing the MM cells to several standard of care agents including the anti-CD138 monoclonal antibodies (moAbs) daratumumab and isatuximab.
Read the fully study here: https://rdcu.be/eidS4
Huge congrats to Catharina Muylaert, her promotor Elke De Bruyne and all other co-authors. Many thanks also to our fantastic collaborators from the team of Jérôme Moreaux, Laboratory for Monitoring Innovative Therapies, CHU Montpellier and from the department of clinical hematology UZBrussel.
We would like to thank Fonds voor Wetenschappelijk Onderzoek (FWO), Wetenschappelijk Fonds Willy Gepts (WFWG) of UZ Brussel, the International Myeloma Society (IMS), the Belgian Hematology Society (BHS) and the Vrije Universiteit Brussel (VUB) for the support.